The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
about
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophiliaActivity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroIn vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinoloneIn vitro activity of BAY 12-8039, a new fluoroquinoloneEfficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Efficient synthesis of substituted 3-azabicyclo[3.1.0]hexan-2-ones from 2-iodocyclopropanecarboxamides using a copper-free Sonogashira coupling.In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rodsTherapeutic advances of new fluoroquinolones.Trovafloxacin: a new fluoroquinolone.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells.The development of new antimicrobial agents.Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
P2860
Q24533461-11EBE123-7EDF-4A74-A236-CE507A839AC5Q24673222-E503CEBF-4101-49C1-800D-D95A403CD46BQ28343293-5412D6CE-27AA-4AB9-A710-937FDC8993F9Q28379381-6B2BC9C1-13A2-409C-8C9E-B294530D8D62Q33692694-77416D16-F3D0-44A7-81CF-C4A1CB796A37Q33693101-03E8F19E-9D30-4C2E-AEFC-73312BA5F451Q33695030-D7F666C9-246D-427E-BAE0-CF2C729FC38AQ33976236-2D822371-0CDE-415E-B9B4-23D121B2580BQ34488194-03E2A034-3D84-4141-BEFF-B4D0D7895E8BQ34734070-E54E9A3E-42CE-4840-B85A-A309DBAF546AQ34734520-1F76748A-7535-4A8E-B28A-F334A3AE44D5Q34746644-DB8CF94F-C0B9-4D10-8AF7-5A299C8A7E6BQ35133082-68B1A282-5613-440C-BFAF-77BE2E40A9FCQ35137076-0A67113A-9505-4EE1-91D8-1A1A3A73B65AQ36181167-E437920B-41C4-423A-A3C8-B2348CF7B0E7Q37879173-03952668-38F1-452D-A31F-1C6F7C11CC77Q39469535-AAC65BE9-7AFA-49A6-94FB-33006DF1F734Q39476076-C70D3380-5BDC-449D-BE18-E78A7F2ED8F3Q39556763-4C24996B-97B3-42C4-A2A7-2FDE14F73D26Q39556938-D158EDF3-CC6A-4BE2-8DA8-037039C6D181Q39783596-1E5BA956-D829-4A84-BB69-B1F84531B400Q42214565-E88314EC-4080-4A0C-936B-B544B9F78876Q42588154-42DBC4FE-B8EB-4849-A8DC-659BD262EA88Q54435973-07C22288-EF83-439F-90DA-4A5E2823BE9A
P2860
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1995
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@en
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@nl
type
label
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@en
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@nl
prefLabel
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@en
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@nl
P2093
P356
P1476
The in-vitro activity of CP 99 ...... n with fluoroquinolone agents.
@en
P2093
P304
P356
10.1093/JAC/35.6.869
P407
P577
1995-06-01T00:00:00Z